Purpose
XLP, protoporphyria
ERYTHROPOIETIC PROTOPORPHYRIA, PROTOPORPHYRIA, EPP
To describe outcomes from the first-in-human study of dersimelagon, an investigational oral selective MC1R agonist, under development for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).